Kavar Capital Partners Group’s Myriad Genetics MYGN Stock Holding History

Kavar Capital Partners Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-200	Closed	-$6K	–	338
2019 Q2	$6K	Buy	+200	New	+$5.65K	﹤0.01%	411
2018 Q3	–	Sell	-200	Closed	-$7K	–	284
2018 Q2	$7K	Hold	200	–	–	﹤0.01%	346
2018 Q1	$6K	Buy	+200	New	+$6.77K	﹤0.01%	359

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kavar Capital Partners Group's MYGN Position: Q3 2019 in Review

Kavar Capital Partners Group sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 200 shares — an estimated $6K sold.

Kavar Capital Partners Group first reported a position in MYGN in Q1 2018 and held it in 3 quarters. The position peaked at $7K in Q2 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Kavar Capital Partners Group reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Kavar Capital Partners Group sold 200 Myriad Genetics shares in Q3 2019, an estimated $6K.
Kavar Capital Partners Group first reported a position in Myriad Genetics in Q1 2018 and held it in 3 quarters.
Kavar Capital Partners Group's Myriad Genetics position peaked at $7K in Q2 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Kavar Capital Partners Group's 13F filing for Q3 2019, filed 12 Nov 2019.